← The Wire
XERSNasdaq
Xeris Biopharma Holdings, Inc.
Pharmaceutical Preparations · CIK 1867096
Develops and commercializes therapies for chronic endocrine and neurological diseases using proprietary formulation technology
red 8-K · 90d
$1.17B
Market cap
$7.74
Last close
+0.7%
1D
+12.2%
5D
2.6M
Volume
Price · last 39 sessions+22.1%
May 4L $5.89 · H $7.74Jun 29
90
Total filings
Jun 11, 2026
Last filing
12/31
Fiscal year end
8-KEquity Issuance · Company UpdateJun 11, 20268-KShareholder VoteJun 5, 202610-Q10-QMay 7, 20268-KResults of OperationsMay 7, 2026DEFA14ADEFA14AApr 23, 2026DEF 14ADEF 14AApr 23, 20268-KExecutive ChangeApr 21, 202610-K10-KMar 2, 20268-KResults of OperationsMar 2, 20268-KReg FD DisclosureFeb 27, 20268-KResults of OperationsJan 8, 20268-KReg FD DisclosureDec 1, 202510-Q10-QNov 6, 20258-KResults of OperationsNov 6, 202510-Q10-QAug 7, 20258-KResults of OperationsAug 7, 20258-KShareholder VoteJun 4, 20258-KReg FD DisclosureJun 3, 202510-Q10-QMay 8, 20258-KResults of OperationsMay 8, 2025DEFA14ADEFA14AApr 23, 2025DEF 14ADEF 14AApr 23, 20258-KExecutive Change · Reg FD DisclosureMar 28, 202510-K10-KMar 6, 20258-KResults of OperationsMar 6, 20258-KExecutive Change · Reg FD DisclosureFeb 24, 20258-KResults of OperationsJan 10, 202510-Q10-QNov 8, 20248-KResults of OperationsNov 8, 202410-Q10-QAug 8, 20248-KResults of OperationsAug 8, 20248-KExecutive ChangeAug 2, 20248-KExecutive Change · Results of OperationsJul 8, 20248-KExecutive Change · Shareholder VoteJun 5, 202410-Q10-QMay 9, 20248-KResults of OperationsMay 9, 2024DEFA14ADEFA14AApr 23, 2024DEF 14ADEF 14AApr 23, 202410-K10-KMar 6, 20248-KMaterial Agreement · Results of OperationsMar 6, 2024SC 13GSCHEDULE 13GFeb 13, 2024SC 13GSC 13GJan 26, 20248-KResults of OperationsJan 4, 202410-Q10-QNov 9, 20238-KResults of OperationsNov 9, 20238-KReg FD DisclosureOct 16, 20238-KMaterial Agreement · New Debt / ObligationSep 29, 20238-KMaterial Agreement · Equity IssuanceSep 27, 202310-Q10-QAug 8, 20238-KResults of OperationsAug 8, 20238-KReg FD DisclosureJun 28, 20238-KShareholder VoteJun 7, 202310-Q10-QMay 9, 20238-KResults of OperationsMay 9, 2023DEFA14ADEFA14AApr 26, 2023DEF 14ADEF 14AApr 26, 20238-KExecutive ChangeMar 29, 20238-KAuditor ChangeMar 17, 202310-K10-KMar 8, 20238-KResults of OperationsMar 8, 2023SC 13GSC 13GFeb 10, 20238-KMaterial AgreementJan 20, 20238-KResults of OperationsJan 5, 202310-Q10-QNov 9, 20228-KResults of OperationsNov 9, 20228-KReg FD DisclosureOct 20, 20228-KMaterial Agreement · New Debt / ObligationOct 3, 202210-Q10-QAug 10, 20228-KResults of OperationsAug 10, 20228-KShareholder VoteJun 8, 2022424B5424B5May 11, 202210-Q10-QMay 11, 20228-KResults of OperationsMay 11, 2022DEFA14ADEFA14AMay 2, 2022DEFA14ADEFA14AApr 28, 2022DEF 14ADEF 14AApr 28, 202210-K10-KMar 11, 20228-KMaterial Agreement · Results of OperationsMar 10, 20228-KCompany UpdateJan 28, 20228-KResults of OperationsJan 18, 2022
Insider Activity
In the 90 days to Mar 2, 2026: 5 sold $1.7M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 2, 2026 | Hecht BethSee Remarks | Sell | 16,567 | $6.24 | $103K |
| Mar 2, 2026 | Hecht BethSee Remarks | Sell | 100 | $7.06 | $706 |
| Feb 2, 2026 | Hecht BethSee Remarks | Sell | 16,667 | $7.45 | $124K |
| Jan 8, 2026 | Mcculloch KevinSee Remarks | Sell | 15,000 | $8.00 | $120K |
| Jan 5, 2026 | Shannon John Patrick JrSee Remarks | Sell | 24,907 | $7.08 | $176K |
| Jan 2, 2026 | Hecht BethSee Remarks | Sell | 16,667 | $7.43 | $124K |
| Dec 19, 2025 | Johnson JohnDirector | Sell | 135,400 | $7.22 | $978K |
| Dec 12, 2025 | Bormann-Kennedy Barbara-Jean AnneDirector | Sell | 15,000 | $7.09 | $106K |
| Dec 1, 2025 | Hecht BethSee Remarks | Sell | 16,667 | $7.01 | $117K |
| Nov 13, 2025 | Shannon John Patrick JrSee Remarks | Sell | 23,242 | $7.46 | $173K |
| Nov 11, 2025 | Hecht BethSee Remarks | Sell | 16,667 | $7.40 | $123K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance